Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blinded, Double Dummy, Active-controlled, Parallel Design, Phase 3 Clinical Trial to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia, Not Adequately Controlled on Statin Therapy

NCT04669041 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04669041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blinded, Double Dummy, Active-controlled, Parallel Design, Phase 3 Clinical Trial to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia, Not Adequately Controlled on Statin Therapy
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
December 8, 2020
Completion date
June 15, 2022
Enrollment
305 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia